Smits, Mark M <br/><br/>
Biliary effects of liraglutide and sitagliptin, a 12-week randomized placebo-controlled trial in type 2 diabetes patients.  [electronic resource] 

 -  Diabetes, obesity & metabolism  12 2016 
 - 1217-1225 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.12748  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Aged<br/>Bile Acids and Salts--metabolism<br/>Blood Glucose--metabolism<br/>Chenodeoxycholic Acid--metabolism<br/>Cholic Acid--metabolism<br/>Deoxycholic Acid--metabolism<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Dipeptidyl-Peptidase IV Inhibitors--therapeutic use<br/>Double-Blind Method<br/>Drug Therapy, Combination<br/>Fasting<br/>Feces--chemistry<br/>Female<br/>Gallbladder--diagnostic imaging<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Liraglutide--therapeutic use<br/>Male<br/>Metformin--therapeutic use<br/>Middle Aged<br/>Organ Size<br/>Postprandial Period<br/>Sitagliptin Phosphate--therapeutic use<br/>Sulfonylurea Compounds--therapeutic use<br/>Ultrasonography<br/>Ursodeoxycholic Acid--metabolism<br/>Glucagon-Like Peptide-1 Receptor Agonists